Drug Trial Radar · NCT03350451
An Extension Study of an Investigational Drug, Lumasiran (ALN-GO1), in Participants With Primary Hyperoxaluria Type 1
Last checked: Nov 20, 2026Latest source record: Apr 25, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
20
Actual
Start
Apr 4, 2018
Primary completion
Feb 7, 2023
Study completion Feb 7, 2023
Sponsor
- Lead sponsor
- Alnylam PharmaceuticalsAlnylam Pharmaceuticals (ALNY)
- Sponsor type
- Industry
- First posted
- Nov 22, 2017
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 6 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the long-term safety and tolerability of lumasiran in participants with Primary Hyperoxaluria Type 1.
Conditions
- PH1
- Primary Hyperoxaluria
- RNAi Therapeutic
- siRNA
- AGT
Interventions
LumasiranDrug
Multiple doses of lumasiran by SC injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With at Least One Adverse Event (AE)Time frame: Baseline (Day -1) up to 54 months
Locations
9 sites in 5 countries. Site status is shown where the registry gives one.
Clinical Trial Site
Bordeaux, France
Clinical Trial Site
Lyon, France
Clinical Trial Site
Paris, France
Clinical Trial Site
Bonn, Germany
Clinical Trial Site
Haifa, Israel
Clinical Trial Site
Jerusalem, Israel
Clinical Trial Site
Amsterdam, Netherlands
Clinical Trial Site
Birmingham, United Kingdom
Clinical Trial Site
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.